Transforming growth factor beta 1 (TGF β1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.

CONCLUSION: The present study indicates that TGFB1 variants have subtype-specific roles in BC and may switch from tumor suppressor to promoter during tumor development, consistent with TGFβ1 dual role in BC pathogenesis. PMID: 29362917 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research

Related Links:

Publication date: Available online 19 February 2019Source: Journal of Bone OncologyAuthor(s): C. Wilson, C. Martin, M.C. WinterAbstractBackgroundAdjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of ‘real world’ data on compliance and patient satisfaction with oral BPs in this population. The aim of our study was to investigate patient reported compliance and toxicity of these drugs in a retrospective cohort study.Patients and methods413 patient were identified as receiving adjuvant oral BPs ...
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
Introduction: In invasive breast cancer, the detection of disseminated tumor cells (DTCs) in the bone marrow (BM) is associated with larger tumor size, axillary lymph node involvement, estrogen (ER) and progesterone (PR) receptor negativity and human epidermal growth factor receptor 2 (HER2) positivity as well as aggressive molecular subtype (non-luminal). In patients with ductal carcinoma in situ (DCIS) any such association has yet to be shown.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Session 30 – Oncology: Breast Source Type: research
Introduction: Breast cancer is the most common cancer it represents the second leading cause of death in the world. A molecular classification of this cancer has been recently established. The molecular classification of breast cancer based on gene expression and then on the protein profile allowed to distinguish five molecular groups: luminal A, luminal B, Her2/neu, basal-like and not classified.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Oral Poster at Breakfast 9 – Breast Source Type: research
ConclusionIt seems that inexperienced physicians may profit from the use of EndoPredict® to avoid an overtreatment. In nodal negative patients and patients with a low Ki67 index, undertreatment can be avoided with the use of EndoPredict® (borderline significance). Further prospective studies with larger study cohorts are needed to further validate this tool.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
NICE has published guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.
Source: NHS Networks - Category: UK Health Source Type: news
mig Kasimir-Bauer Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, isolation of cfDNA and CTC in an “all from one tube” format is desired. We investigated whether cfDNA variant sequencing from CTC-depleted blood (CTC-depl. B; obtained after positive immunomagnetic isolation of CTCs (AdnaTest EMT-2/Stem Cell Select, QIAGEN)) impacts the results compared to cfDNA variant sequencing from matched whole blood (WB). ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Edge SB, Hortobagyi GN, Giuliano AE Abstract INTRODUCTION: Cancer staging has historically been based solely on the anatomic extent of the tumor (T), spread to lymph nodes (N), and presence of distant metastases (M). More recently biologic factors have been added to modify TNM stage groups to provide more accurate prognosis for patients. Areas covered: The American Joint Committee on Cancer (AJCC) updated breast cancer staging in 2016 to include T, N, M, tumor grade and expression of estrogen and progesterone receptors and HER2. Addition of these factors changed the stage group for a large fraction of case...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
This study aimed at investigating the relationship between the intakes of micronutrients involved in one-carbon metabolism with breast cancer (BrCa) and its subtype's odds. METHODS: Nutrients' intake from diet and supplements were collected through interviewing 151 cases and 154 controls by a 168-item semiquantitative food frequency questionnaire. Logistic regression was used to determine the relationship between dietary and/or total intake of studied nutrients and odds of BrCa and its subtypes. RESULTS: After adjusting the effects of confounding variables in the models, the odds of BrCa was significantly lower in ...
Source: International Journal for Vitamin and Nutrition Research - Category: Nutrition Tags: Int J Vitam Nutr Res Source Type: research
ConclusionsBPE could play a crucial role as an imaging bridge to molecular breast cancer subtype allowing an additional risk stratification in the field of breast MRI and targeted screening tests. Luminal B (HER2-) tumors could prevail in case of mild BPE on CE-MRI examinations and TN tumors in patients with marked BPE. Further studies on larger series are needed to confirm this hypothesis.
Source: European Journal of Radiology - Category: Radiology Source Type: research
PMID: 30770489 [PubMed - in process]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Statistics | Study | Women